Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Colorectal and gastric cancer in 2015

The development of new agents and molecular classifications

Nature Reviews Clinical Oncology volume 13, pages 69–70 (2016)Cite this article

Subjects

In a little over the past year, several clinical trials have evaluated new drugs in patients with metastatic colorectal cancer and gastric cancer. Furthermore, genomics studies that attempted to unravel the molecular characteristics of colorectal and gastric cancer were published in 2015. The results of these endeavours will influence clinical practice in 2016 and beyond.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065–1075 (2014).

    Article  CAS  Google Scholar 

  2. Maier, R. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909–1919 (2015).

    Article  Google Scholar 

  3. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303–312 (2013).

    Article  CAS  Google Scholar 

  4. Tabernero, J. et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 16, 937–948 (2015).

    Article  CAS  Google Scholar 

  5. Dienstmann, R. et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 5, 1–12 (2015).

    Article  Google Scholar 

  6. Lida, M. et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 15, 1196–1206 (2013).

    Article  Google Scholar 

  7. Le, D. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

    Article  CAS  Google Scholar 

  8. Fuchs, C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro−oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014).

    Article  CAS  Google Scholar 

  9. Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro−oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224–1235 (2014).

    Article  CAS  Google Scholar 

  10. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).

  11. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eric Van Cutsem is at the Digestive Oncology, University Hospitals Leuven and KU Leuven, Herestraat 49, 3000 Leuven, Belgium.,

    Eric Van Cutsem

  2. Department of Medicine, Michel Ducreux is at the Gastrointestinal Unit, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France, and the Faculty of Medicine, Paris Sud University, 63 Rue Gabriel Péri, 94270 Le Kremlin Bicêtre, France.,

    Michel Ducreux

Authors
  1. Eric Van Cutsem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Ducreux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Van Cutsem.

Ethics declarations

Competing interests

E.V.C. has received research grants from Amgen, Bayer, Boehringer, Celgene, Ipsen, Lilly, Merck Serono, Novartis, Roche, and Sanofi. M.D. is on the advisory board and has attended symposia for Amgen, Celgene, Lilly, Merck, Novartis, and Roche. M.D.'s wife is employed by Sandoz (Novartis group).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van Cutsem, E., Ducreux, M. The development of new agents and molecular classifications. Nat Rev Clin Oncol 13, 69–70 (2016). https://doi.org/10.1038/nrclinonc.2015.217

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.217

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer